Guide

Global pharmaceutical GMP readiness

Pharmaceutical manufacturers selling into more than one market do not need a different quality system per country — they need one ICH Q10 pharmaceutical quality system that is tuned to each regulator's local expectations. The global spine is ICH (Q7 for APIs, Q9 for risk, Q10 for the PQS, Q1A for stability, Q2 for analytical methods, Q8/Q11 for development, M7 for impurities) plus PIC/S, the inspectorate-level convergence body that 50+ authorities (FDA, EMA, MHRA, Swissmedic, PMDA via observer, Health Canada, TGA, ANVISA, MFDS, and others) belong to. This hub explains how that global layer maps to each country's GMP rules, what changes in inspection style, and which data-integrity, QP, GDP, and serialization obligations differ. Follow the country links below for the local detail; use this page to plan the program.

Start free trial Free trial, no credit card, onboard in days, not months.

The global spine — ICH, PIC/S, and WHO TRS

ICH Q10 defines the pharmaceutical quality system (PQS) used worldwide as the design pattern: management responsibility, process performance and product quality monitoring, CAPA, change management, and management review. ICH Q9 (revised 2023) is the risk-management backbone. ICH Q7 sets cGMP for active pharmaceutical ingredients and is adopted (with local annexes) by virtually every regulator. PIC/S publishes the GMP guide that EU/EEA, MHRA, Swissmedic, Health Canada, TGA, MFDS, ANVISA, and many others use as their inspection reference — Part I (finished products), Part II (APIs, mirroring ICH Q7), and the Annexes (Annex 1 sterile, Annex 11 computerised systems, Annex 15 qualification/validation, Annex 16 QP release). WHO TRS GMP texts remain the reference for countries without PIC/S membership and for prequalification.

Where countries diverge

The PQS is global; the divergence sits in five layers. (1) Release: the EU/UK/Switzerland require Qualified Person batch certification; FDA does not. (2) Distribution: EU GDP, UK GDP, and Swissmedic GDP are explicit standards; the US uses 21 CFR 205/DSCSA instead. (3) Serialization: DSCSA (US), EU FMD/2D Datamatrix, Brazil SNCM, China drug code, India barcoding, South Korea KGMP serialization, and Saudi RSD all require different identifiers and reporting. (4) Data integrity: MHRA, FDA, WHO, PIC/S PI 041, and NMPA Annex on data integrity overlap but cite different examples; ALCOA+ is the common language. (5) Inspection style: FDA issues Form 483 and Warning Letters; EU/PIC/S inspectorates issue inspection reports with critical/major/other classifications and may suspend the manufacturing licence or GMP certificate.

Mutual recognition and inspection reliance

The most useful global lever is mutual recognition. The EU–US MRA recognizes each other's GMP inspections for most human drugs (since 2017–2019). The EU has parallel MRAs with Switzerland, Canada, Japan, Australia, New Zealand, and Israel. PIC/S members rely heavily on each other's inspection reports. MDSAP is the medical-device parallel; for pharma, the equivalent is the EMA/FDA/HMA/MHRA collaborative inspection program. A clean PIC/S-style inspection report from one authority frequently reduces or removes routine on-site inspection by another, but it does NOT replace local marketing authorization, QP release, or serialization compliance.

Country guides — start here

Use the country guides linked below for the local-law detail. Each guide assumes you already have an ICH Q10 PQS and focuses on the country-specific layer: regulator, legal basis, market entry, QP/release model, GDP, serialization, language and labeling, inspection patterns, and a 90–180 day readiness path. Definitions of terms used throughout (cGMP, ALCOA+, ICH Q10, ICH Q9, ICH Q7, QP release, Annex 1, Annex 11, GAMP 5, CAPA, deviation, OOS, EU GDP, DSCSA) live in the glossary and are linked inline.

A pragmatic global readiness path

Days 0–30: confirm ICH Q10 PQS coverage; map products to markets; identify QP, GDP holder, and serialization endpoints per country. Days 31–90: align one global SOP set (deviation, CAPA, change control, OOS, complaint, data integrity per ALCOA+) and write thin country annexes; close the gap on Annex 1 (sterile) and Annex 11 / GAMP 5 (computerised systems) since these are the most common inspection findings worldwide. Days 91–180: run a mock PIC/S-style inspection; close findings; schedule the first real inspection in the lead market, then leverage MRA/reliance for the rest.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

ICH Q10

The international model for a Pharmaceutical Quality System covering the entire product lifecycle from development to discontinuation.

ICH Q9

International guideline that mandates risk-based decision-making across the pharma product lifecycle. Underpins everything from supplier qualification to PPQ batch count.

ICH Q7

The international GMP standard for API manufacture — adopted as FDA guidance and EU GMP Part II.

QP release

EU GMP — only a named Qualified Person can certify a batch for market release.

EU GDP

Binding EU/EEA standard for wholesale distribution of medicinal products — quality system, Responsible Person, qualified premises and transport, supplier and customer verification, FMD safeguards, returns, recalls, transportation.

ALCOA+

The nine-letter mnemonic regulators use to grade your data integrity — and what every Part 11 audit really tests.

EU Annex 11

European equivalent of 21 CFR Part 11 — rules for computerised systems in GMP.

EU GMP Annex 1 Sterile

EU GMP Annex 1 (revision effective 25 August 2023, with full lyophilisation-section compliance from 25 August 2024) is the world's most influential sterile-manufacturing standard — adopted by EU, MHRA

GAMP 5

ISPE's risk-based framework for validating computerised systems in regulated industries.

21 CFR 211

The FDA cGMP rule that governs every step of finished-drug manufacturing — facilities, equipment, components, production, packaging, labels, lab controls, records and complaints.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Industries this hits hardest

Frequently asked

Do we need a separate quality system per country?

No. The PQS is built once to ICH Q10 and PIC/S Part I/II; country differences are handled as thin overlays — QP release for EU/UK/CH, DSCSA serialization for the US, GDP records for Europe, language/labeling for each market. Trying to run parallel QMSs per country is the most common root cause of data-integrity findings.

Does an EU GMP certificate help us in the US, and vice versa?

Yes, via the EU–US MRA: routine GMP inspections are recognized for most human drugs, so a current EU GMP certificate (or FDA Establishment Inspection Report) is normally accepted as evidence of GMP compliance by the other authority. It does NOT replace marketing authorization, NDA/MAA-specific PAI, or local serialization/QP obligations.

Where do most multi-market manufacturers fail their first inspection?

Three areas dominate: (1) data integrity — audit trails not reviewed, shared user accounts, unlocked spreadsheets used for GMP decisions; (2) Annex 1 — contamination control strategy gaps, environmental monitoring trending; (3) supplier qualification and change control of outsourced operations. All three are inspection priorities across FDA, EU, MHRA, and PIC/S members.

Is WHO GMP the same as PIC/S GMP?

Closely aligned but not identical. WHO TRS GMP is the reference for countries without PIC/S membership and for WHO prequalification; PIC/S GMP is the inspectorate-level convergence text used by 50+ authorities. The technical content is largely the same; PIC/S annexes (especially Annex 1, Annex 11, PI 041 on data integrity) are more detailed.

How long does a full multi-market roll-out take?

From a working ICH Q10 PQS, 6–12 months per additional market is typical: 4–6 weeks for the country annex and labeling, 2–4 months to clear local marketing authorization or variation, and 2–6 months until the first local inspection or reliance decision. The path shortens substantially when MRAs apply (EU–US, EU–CH, EU–CA, EU–JP, EU–AU).

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →